Here are the 10-K annual reports from Insulet Corporation (PODD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow PODD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PODD filings page.
Insulet Corporation filed its annual report describing how it develops and sells the tubeless Omnipod insulin delivery platform for people with insulin‑dependent diabetes. The company highlights Omnipod 5’s automated insulin delivery, broad CGM integrations, and smartphone control, along with expansion into insulin‑requiring type 2 diabetes and 25 countries.
Insulet reports heavy reliance on Omnipod products and intermediary distributors, ongoing investments in new algorithms and next‑generation systems, and a global manufacturing footprint in the U.S., Malaysia, China, and a planned facility in Costa Rica. As of December 31, 2025, the company had about 5,400 employees and extensive patent protection through 2047, while outlining detailed regulatory, reimbursement, competition, and supply‑chain risks.